Recurrent phaeochromocytoma along the laparoscopic portal sites

Abstract

from the STIM and TWISTER trials, when imatinib was discontinued after complete molecular remission for 2 years, and most relapses occurred within 6 months. 5,6 We would expect the outcome for imatinib cessation in lesser degrees of remission to be worse. Imatinib therapy has been associated with congenital malformations and its use is not recommended in pregnancy. Interferon has, however, been shown in several observational studies to be safe in pregnancy with minimal risk of teratogenicity. 7 Interferon maintenance has also been shown to maintain remission in the majority of patients who ceased imatinib in a series 8 where many patients were not in MR. 4,5 We consider this approach of transition from TKI to (pegylated) interferon alpha is a safe and reasonable option in women wanting to become pregnant who are yet to achieve MR. 4,5